OneDigital Investment Advisors LLC Purchases 19,862 Shares of Pfizer Inc. (NYSE:PFE)

OneDigital Investment Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 16.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 143,116 shares of the biopharmaceutical company’s stock after purchasing an additional 19,862 shares during the period. OneDigital Investment Advisors LLC’s holdings in Pfizer were worth $3,797,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Passumpsic Savings Bank lifted its stake in shares of Pfizer by 8.4% in the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company’s stock valued at $743,000 after purchasing an additional 1,998 shares during the last quarter. Virtu Financial LLC purchased a new position in Pfizer during the third quarter worth $1,499,000. Westside Investment Management Inc. increased its position in Pfizer by 7.7% during the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company’s stock valued at $404,000 after acquiring an additional 1,004 shares during the last quarter. Diamant Asset Management Inc. increased its position in Pfizer by 8.4% during the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 660 shares during the last quarter. Finally, Morse Asset Management Inc bought a new stake in shares of Pfizer in the 3rd quarter worth about $2,649,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday. They issued a “neutral” rating and a $24.00 price objective on the stock. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $29.57.

Pfizer Stock Performance

PFE stock opened at $22.54 on Wednesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm has a market cap of $127.83 billion, a price-to-earnings ratio of 15.99, a PEG ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a 50-day simple moving average of $24.75 and a two-hundred day simple moving average of $26.08.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.